FIGURE

Figure 1

ID
ZDB-FIG-210125-41
Publication
Kotini et al., 2020 - Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos
Other Figures
All Figure Page
Back to All Figure Page
Figure 1

Derazantinib inhibits vascular development in vivo in a dose-dependent manner. Confocal images of GFP+ blood vessels in the trunk of Tg(fli1:EGFP)y1 zebrafish embryos at 26 hpf (ae) or 45 hpf (fj) after exposure to DMSO as vehicle control (a and f) or increasing concentrations of DZB in the swimming water (be and gj). Blood vessel development was disrupted using concentrations between 0.1 and 3 µM DZB. (k) Quantitative analysis of ISV sprouts that had reached the top roof and started to form the DLAV were normalised to the total number of ISVs per embryo (n ≥ 15 embryos per treatment were analysed from three independent experiments), embryos were treated using increasing concentrations of DZB. (l) Quantitative analysis of ISV sprouts that are disconnected at the DLAV were normalised to the total number of ISVs-1 (total number of connections) per embryo (n ≥ 15 embryos per treatment were analysed from three independent experiments) and embryos were treated using increasing concentrations of DZB. Data in k,l represent mean ± S.E.M. (error bars), ns: not significant, ** p < 0.01, *** p < 0.001. Arrows indicate thinner blood vessels, arrowheads show disconnected blood vessels and asterisks mark sprouting defects. Scale bar, 50 µm. ISV, intersegmental vessel; DLAV, dorsal longitudinal anastomotic vessel; DA, dorsal aorta; PCV, posterior cardinal vein. See also Figure S1.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Pharmaceuticals (Basel)